ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$11.82
0.45 (3.96%)
▲
5d:
+0.17%
30d:
-6.56%
90d:
+125.14%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
15d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 16, 2026 at $11.80 · last confirmed Oct 19, 2026
Strength: 7.6/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $11.82, which is considered slightly low relative to its 30-day fair value range of $11.73 to $13.54.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $11.08, while resistance sits at $13.05. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.82 (+42.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $11.08, while resistance sits at $13.05. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.82 (+42.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.73 -
$13.54
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 42.3% below Wall St target ($16.82)
- NEUTRAL: Bottoming setup forming (42/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$11.73 -
$13.54
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$11.08
Resistance Level
$13.06
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.50
Wall Street Target
$16.82
(+42.3%)
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-248.8%
Share & Embed Analysis
Last updated: October 24, 2026 11:27 AM ET
Data refreshes hourly during market hours. Next update: 12:27 PM
Data refreshes hourly during market hours. Next update: 12:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
